Actively Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2024-11-20
80
Participants Needed
30
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
CONDITIONS
Official Title
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agreed to participate and signed informed consent with good compliance
- Age between 18 and 75 years at consent
- ECOG performance status of 0 to 2
- Expected survival longer than 3 months
- Histologically confirmed B-cell lymphoma meeting 2022 WHO criteria, including relapsed/refractory indolent B-cell lymphoma or diffuse large B cell lymphoma (DLBCL)
- For relapsed/refractory indolent B-cell lymphoma, received at least one prior systemic standard therapy
- At least one measurable lesion
- Adequate major organ function
- Female participants of reproductive age agree to use contraception during the study and for 6 months after
- Negative serum pregnancy test within 7 days prior to enrollment; non-lactating
- Male participants agree to use contraception during the study and for 6 months after
You will not qualify if you...
- Other malignant tumors within 3 years before first treatment
- Known or suspected central nervous system involvement
- Prior allogeneic stem cell transplant or autologous stem cell transplant within 3 months before first treatment for relapsed/refractory indolent B-cell lymphoma
- Toxic reactions from prior treatments not recovered to Grade 1 or less per NCI-CTC, excluding hair loss and fatigue
- Conditions affecting oral drug absorption such as inability to swallow, chronic diarrhea, or intestinal obstruction
- Major surgery or significant trauma within 28 days before starting treatment
- Hyperkinetic or venous thrombosis events within 6 months before first medication
- History of psychotropic drug abuse or uncontrolled mental disorders
- Any severe or uncontrolled diseases
- Received live or mRNA vaccines within 4 weeks before first dose or planned during the study
- Participation in other antitumor drug trials within 4 weeks before first medication
- Investigator judgment of serious concomitant diseases or other reasons making participation unsafe or unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 30 locations
1
Cancer Hospital Chinise Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Not Yet Recruiting
2
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China, 730000
Not Yet Recruiting
3
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510000
Not Yet Recruiting
4
Guigang City People's Hospital
Guigang, Guangxi, China, 537000
Not Yet Recruiting
5
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Not Yet Recruiting
6
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Not Yet Recruiting
7
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Not Yet Recruiting
8
PuYang AnYang District Hospital
Anyang, Henan, China, 450000
Not Yet Recruiting
9
Puyang People's Hospital
Puyang, Henan, China, 457000
Not Yet Recruiting
10
Henan Provincial People's Hospital
Zhengzhou, Henan, China, 450000
Not Yet Recruiting
11
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China, 457000
Not Yet Recruiting
12
Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy
Wuhan, Hubei, China, 430022
Not Yet Recruiting
13
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, China, 430030
Not Yet Recruiting
14
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441000
Not Yet Recruiting
15
Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China, 410013
Not Yet Recruiting
16
Zhuzhou Central Hospital
Zhuzhou, Hunan, China, 412000
Not Yet Recruiting
17
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China, 10000
Not Yet Recruiting
18
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China, 210000
Not Yet Recruiting
19
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Not Yet Recruiting
20
The second Hospital of dalian
Dalian, Liaoning, China, 116000
Not Yet Recruiting
21
The Second Affiliated Hospital Of Xi'an Jiaotong University(Xibei Hospital)
Xi'an, Shaanxi, China, 710004
Not Yet Recruiting
22
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 250117
Actively Recruiting
23
Tai'an Central Hospital
Tai’an, Shandong, China, 271000
Not Yet Recruiting
24
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China, 200063
Not Yet Recruiting
25
Shanxi Cancer Hospital
Taiyuan, Shanxi, China, 030000
Not Yet Recruiting
26
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China, 646000
Not Yet Recruiting
27
Zigong First People's Hospital
Zigong, Sichuan, China, 643000
Not Yet Recruiting
28
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China, 300122
Not Yet Recruiting
29
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300202
Not Yet Recruiting
30
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 830000
Not Yet Recruiting
Research Team
Z
Zengjun Li, Doctor
CONTACT
F
Fei Li, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here